Immunophenotyping of Human Regulatory T-Cells from Peripheral Blood Mononuclear Cells

Regulatory T cells, or Tregs, are a unique type of CD4⁺ T cell that act as the immune system's brakes-they stop it from turning against the body's own tissues. For about twenty years now, researchers have been digging into what sets Tregs apart from other T cells, both in their composition and function (1). Markers like CD25 (IL-2Rα), Foxp3, and CTLA-4 usually show up when Tregs are active, but these markers aren't always reliable-they can shift depending on where the cells are and what they are doing. Foxp3 is a transcription factor that Tregs need to develop and function. Mutations on Foxp3 gene lead to serious autoimmune diseases like immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome. Lately, studies have uncovered even more variety within Tregs by finding subsets with markers like Helios, TIGIT, CD127 (which is usually low in Tregs), and neuropilin-1. Identifying and measuring Tregs accurately is important not only in research but also in the clinic. Identifying Tregs on patient samples provides a clear picture of what is going on with their immune system-whether it is an autoimmune disease, a transplant, or cancer treatment. Flow cytometry has become a go-to tool for identifying, typing, and subclassifying subsets. It helps  showing how Tregs work, how stable they are, and how well they keep other immune cells in check. By profiling Tregs, doctors can group patients more accurately and find biomarkers that tell you if a treatment's working or if a disease is getting worse. Better protocols to test Treg mean more personalized immune therapies. Tregs are serious power players when it comes to immune suppression, and being able to profile them precisely-whether in animals or people-is important for both science and medical care.